The Food and Drug Administration (FDA) granted accelerated approval to dostarlimab for use in select patients with operable rectal cancer. This approval applies to stage II/III patients identified with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) rectal cancer, representing approximately 3% of locally advanced cases. Patients achieving a complete response may potentially avoid standard treatment, which typically includes chemotherapy, radiation, and surgery.
The AZUR-1 trial demonstrated that the majority of patients with dMMR/MSI-H rectal cancers and other solid tumors treated with dostarlimab achieved a complete response and were able to avoid surgery. Principal investigator Andrea Cercek noted the potential for neoadjuvant PD-1 inhibition to eradicate the need for traditional therapies in a subset of patients. An exploratory analysis of AZUR-1 showed that 76% of evaluable patients had no evidence of cancer a year or more after treatment, with no recurrences reported after more than 2 years of follow-up.
Adverse events observed in the AZUR-1 trial included fatigue, rash, diarrhea, and pruritus. Grade 3 adverse events included diabetes, lung infection, hypothyroidism, encephalitis, and neutropenia. The labeling notes the potential for immune-mediated adverse events. Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial. Dostarlimab has multiple approved indications in endometrial cancer and is approved for previously treated dMMR recurrent or advanced solid tumors.